Gaboxadol, a selective extrasynaptic GABA(A) agonist, does not generalise to other sleep-enhancing drugs: a rat drug discrimination study
| Autor: | L.M. McDonald, W. F. Sheppard, Peter H. Hutson, F.D. Tattersall, Bindi Sohal, S.M. Staveley |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Drug
Agonist Male Zolpidem Tiagabine medicine.drug_class media_common.quotation_subject Pharmacology Generalization Psychological Discrimination Learning Rats Sprague-Dawley Cellular and Molecular Neuroscience medicine Animals Drug Interactions GABA Agonists media_common Zopiclone Dose-Response Relationship Drug business.industry GABAA receptor musculoskeletal neural and ocular physiology Isoxazoles Rats Indiplon Conditioning Operant Drug Evaluation business Sleep Gaboxadol medicine.drug |
| Zdroj: | Neuropharmacology. 52(3) |
| ISSN: | 0028-3908 |
| Popis: | Gaboxadol is a selective extrasynaptic GABA(A) receptor agonist (SEGA) which enhances slow-wave sleep, and may act principally at extrasynaptic GABA(A)alpha4betadelta receptors. Drug discrimination is a very useful approach for exploring in vivo pharmacological similarities and differences between compounds and was therefore used to compare gaboxadol and zolpidem, an established hypnotic drug, against zopiclone, S-zopiclone, indiplon and tiagabine, all of which have been reported to enhance sleep. Gaboxadol generalised to itself, but not to zolpidem, zopiclone, S-zopiclone, R-zopiclone, indiplon or tiagabine. By contrast, zolpidem generalised to itself, zopiclone, S-zopiclone and indiplon, but not to R-zopiclone (the inactive enantiomer of zopiclone), gaboxadol or tiagabine. This suggests that zolpidem, zopiclone, S-zopiclone and indiplon share a discriminative stimulus, which may be mediated by their efficacy at GABA(A)alpha1betagamma receptors. Gaboxadol and tiagabine each have a different discriminative stimulus from all the other drugs tested. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect